{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:33:10Z","timestamp":1792798390356,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008940.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000}}],"reference-count":195,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008940.pub4","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:23:46Z","timestamp":1759227826000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacotherapies for cannabis use disorder"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6904-2247","authenticated-orcid":false,"given":"Francesca","family":"Spiga","sequence":"additional","affiliation":[{"name":"NIHR Bristol Evidence Synthesis Group; University of Bristol; Bristol UK"},{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Parkhouse","sequence":"additional","affiliation":[{"name":"NIHR Bristol Evidence Synthesis Group; University of Bristol; Bristol UK"},{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Temerty Faculty of Medicine; University of Toronto; Toronto Canada"},{"name":"Institute of Medical Science; University of Toronto; Toronto Canada"},{"name":"Institute for Mental Health Policy Research; Centre for Addiction and Mental Health; Toronto Canada"},{"name":"Addictions Division; Centre for Addiction and Mental Health; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Savovi\u0107","sequence":"additional","affiliation":[{"name":"NIHR Bristol Evidence Synthesis Group; University of Bristol; Bristol UK"},{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"},{"name":"NIHR Applied Research Collaboration West (ARC West); University Hospitals Bristol and Weston NHS Foundation Trust; Bristol United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[{"name":"Translational Addiction Research Laboratory; Centre for Addiction and Mental Health; University of Toronto; Toronto Canada"},{"name":"Institute of Medical Science, Temerty Faculty of Medicine; University of Toronto; Toronto, Ontario Canada"},{"name":"Addictions Division; Centre for Addiction and Mental Health; Toronto, Ontario Canada"},{"name":"Department of Psychiatry; Temerty Faculty of Medicine, University of Toronto,; Toronto, Ontario Canada"},{"name":"Department of Pharmacology & Toxicology; University of Toronto; Toronto, Ontario Canada. Campbell Family Mental Health Research Institute; Centre for Addiction and Mental Health; Toronto, Ontario Canada. Institute for Mental Health Policy Research; Centre for Addiction and Mental Health; Toronto, Ontario Canada. Department of Family and Community Medicine; University of Toronto; Toronto, Ontario Canada. Waypoint Research Institute; Waypoint Centre for Mental Health Care; Penetanguishene, Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-1055","authenticated-orcid":false,"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre; Monash University; Frankston Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"10.1002\/14651858.CD008940.pub4-BIB0001|cit1","unstructured":"United Nations Office on Drugs and Crime World Drug Report 2024 https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/world-drug-report-2024.html"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/wps.20735","article-title":"Assessing the public health impacts of legalizing recreational cannabis use: the US experience","volume":"19","author":"Hall","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"100227","DOI":"10.1016\/j.lanepe.2021.100227","article-title":"Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates","volume":"10","author":"Manthey","year":"2021","journal-title":"Lancet Regional Health - Europe"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"591979","DOI":"10.3389\/fpsyt.2020.591979","article-title":"Cannabis legalization and acute harm from high potency cannabis products: a narrative review and recommendations for public health","volume":"11","author":"Matheson","year":"2020","journal-title":"Frontiers Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD008940.pub4-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S2215-0366(22)00161-4","article-title":"Association of cannabis potency with mental ill health and addiction: a systematic review","volume":"9","author":"Petrilli","year":"2022","journal-title":"Lancet. Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders dsm.psychiatryonline.org 2013 5th","DOI":"10.1176\/appi.books.9780890425596"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0007|cit7","unstructured":"United Nations Office on Drugs and Crime World Drug Report 2017 www.unodc.org\/wdr2017"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0008|cit8","unstructured":"United Nations Office on Drugs and Crime World Drug Report 2022 www.unodc.org\/unodc\/en\/data-and-analysis\/world-drug-report-2022.html"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0009|cit9","unstructured":"ECOWAS Commission The West African Epidemiology Network on drug use (WENDU) Report. Statistics and trends on illicit drug use and supply (2018-2019) https:\/\/ecowas.int\/wp-content\/uploads\/2022\/03\/WENDU-REPORT-ENGLISH.pdf"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub4-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"Article 1","DOI":"10.14221\/aihjournal.v3n3.1","article-title":"Review of cannabis use among Aboriginal and Torres Strait Islander people","volume":"3","author":"Butt","year":"2022","journal-title":"Journal of the Australian Indigenous Health Info Net"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"103081","DOI":"10.1016\/j.drugpo.2020.103081","article-title":"Non-medical cannabis use among Indigenous Canadians: a systematic review of prevalence and associated factors","volume":"90","author":"Wennberg","year":"2021","journal-title":"International Journal on Drug Policy"},{"issue":"5","key":"10.1002\/14651858.CD008940.pub4-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/schbul\/sbae072","article-title":"The role of social deprivation and cannabis use in explaining variation in the incidence of psychotic disorders: findings from the EU-GEI study","volume":"50","author":"Brink","year":"2024","journal-title":"Schizophrenia Bulletin"},{"issue":"11","key":"10.1002\/14651858.CD008940.pub4-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"e2136571","DOI":"10.1001\/jamanetworkopen.2021.36571","article-title":"Sociodemographic characteristics associated with and prevalence and frequency of cannabis use among adults in the US","volume":"4","author":"Jeffers","year":"2021","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s42238-020-00052-y","article-title":"Changes in cannabis use according to socioeconomic status among Finnish adolescents from 2000 to 2015","volume":"2","author":"Knaappila","year":"2020","journal-title":"Journal on Cannabis Research"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0015|cit15","unstructured":"Substance Abuse and Mental Health Services Administration; Office of Applied Studies Treatment episode data set (TEDS): 1996-2006. National admissions to substance abuse treatment services www.oas.samhsa.gov\/copies.cfm"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0016|cit16","unstructured":"European Monitoring Centre for Drugs and Drug Addiction Cannabis drug profile www.emcdda.europa.eu\/publications\/drug-profiles\/cannabis"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1151\/ASCP07414","article-title":"Marijuana dependence and its treatment","volume":"4","author":"Budney","year":"2007","journal-title":"Addiction Science & Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1874473710801010081","article-title":"The chronic effects of cannabis on memory in humans: a review","volume":"1","author":"Solowij","year":"2008","journal-title":"Current Drug Abuse Reviews"},{"issue":"9698","key":"10.1002\/14651858.CD008940.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(09)61037-0","article-title":"Adverse health effects of non-medical cannabis use","volume":"374","author":"Hall","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMra1402309","article-title":"Adverse health effects of marijuana use","volume":"370","author":"Volkow","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S2215-0366(14)70307-4","article-title":"Young adult sequelae of adolescent cannabis use: an integrative analysis","volume":"1","author":"Silins","year":"2014","journal-title":"Lancet Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drugalcdep.2015.08.034","article-title":"Adolescent substance use and educational attainment: an integrative data analysis comparing cannabis and alcohol from three Australasian cohorts","volume":"156","author":"Silins","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1002\/14651858.CD008940.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1017\/S0033291703008560","article-title":"Attributes of long-term heavy cannabis users: a case-control study","volume":"33","author":"Gruber","year":"2003","journal-title":"Psychological Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub4-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","article-title":"Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study","volume":"2","author":"Di Forti","year":"2015","journal-title":"Lancet. Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD008940.pub4-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"e030178","DOI":"10.1161\/JAHA.123.030178","article-title":"Association of cannabis use with cardiovascular outcomes among US adults","volume":"13","author":"Jeffers","year":"2024","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"106479","DOI":"10.1016\/j.addbeh.2020.106479","article-title":"What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis","volume":"109","author":"Leung","year":"2020","journal-title":"Addictive Behaviors"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2217\/npy.13.90","article-title":"Cannabis use, harms and the management of cannabis use disorder","volume":"4","author":"Copeland","year":"2014","journal-title":"Neuropsychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aap.2014.12.015","article-title":"Impact of age at onset of cannabis use on cannabis dependence and driving under the influence in the United States","volume":"76","author":"Le Strat","year":"2015","journal-title":"Accident Analysis & Prevention"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0029|cit29","volume-title":"Health and Psychological Effects of Cannabis Use","author":"Hall","year":"2001"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1465-3362.2009.00132.x","article-title":"An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results","volume":"29","author":"Minozzi","year":"2010","journal-title":"Drug and Alcohol Review"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/archgenpsychiatry.2011.5","article-title":"Cannabis use and earlier onset of psychosis","volume":"68","author":"Large","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.comppsych.2012.12.021","article-title":"Cannabis use and cannabis use disorders among individuals with mental illness","volume":"54","author":"Lev-Ran","year":"2013","journal-title":"Comprehensive Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/10550490802019519","article-title":"Is there evidence for symptoms of cannabis withdrawal in the National Epidemiologic Survey of Alcohol and Related Conditions?","volume":"17","author":"Agrawal","year":"2008","journal-title":"American Journal on Addictions"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.yco.0000218592.00689.e5","article-title":"The cannabis withdrawal syndrome","volume":"19","author":"Budney","year":"2006","journal-title":"Current Opinion in Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD008940.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1360-0443.2008.02158.x","article-title":"Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents","volume":"103","author":"Chung","year":"2008","journal-title":"Addiction"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/10550490500418997","article-title":"Cannabis withdrawal among non-treatment-seeking adult cannabis users","volume":"15","author":"Copersino","year":"2006","journal-title":"American Journal on Addictions"},{"issue":"9","key":"10.1002\/14651858.CD008940.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.4088\/JCP.v69n0902","article-title":"Cannabis withdrawal in the United States: results from NESARC","volume":"69","author":"Hasin","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD008940.pub4-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.addbeh.2008.02.001","article-title":"Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence","volume":"33","author":"Cornelius","year":"2008","journal-title":"Addictive Behaviors"},{"issue":"15","key":"10.1002\/14651858.CD008940.pub4-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1017\/S0033291715001178","article-title":"Examining the profile of high-potency cannabis and its association with severity of cannabis dependence","volume":"45","author":"Freeman","year":"2015","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00213-011-2480-4","article-title":"Characterizing smoking topography of cannabis in heavy users","volume":"220","author":"McClure","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/add.12508","article-title":"Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study","volume":"109","author":"Van der Pol","year":"2014","journal-title":"Addiction (Abingdon, England)"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0042|cit42","first-page":"174","article-title":"Prospective assessment of cannabis withdrawal in adolescents with cannabis dependence: a pilot study","volume":"47","author":"Milin","year":"2008","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1037\/0021-843X.112.3.393","article-title":"The time course and significance of cannabis withdrawal","volume":"112","author":"Budney","year":"2003","journal-title":"Journal of Abnormal Psychology"},{"issue":"7","key":"10.1002\/14651858.CD008940.pub4-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/add.15743","article-title":"Clinical management of cannabis withdrawal","volume":"117","author":"Connor","year":"2022","journal-title":"Addiction (Abingdon, England)"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub4-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/add.14525","article-title":"Increasing potency and price of cannabis in Europe, 2006-19","volume":"114","author":"Freeman","year":"2019","journal-title":"Addiction (Abingdon, England)"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub4-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"e0230167","DOI":"10.1371\/journal.pone.0230167","article-title":"Mapping cannabis potency in medical and recreational programs in the United States","volume":"15","author":"Cash","year":"2020","journal-title":"PloS One"},{"issue":"5","key":"10.1002\/14651858.CD008940.pub4-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005336.pub4","article-title":"Psychosocial interventions for cannabis use disorder","author":"Gates","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD008940.pub4-BIB0048|cit48","first-page":"243","article-title":"Pharmacotherapy for cannabis dependence: how close are we?","volume":"23","author":"Vandrey","year":"2009","journal-title":"Central Nervous System Drugs"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/bs.irn.2016.02.005","article-title":"Screening medications for the treatment of cannabis use disorder","volume":"126","author":"Panlilio","year":"2016","journal-title":"International Review of Neurobiology"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0740-5472(00)00148-3","article-title":"Clinical profile of participants in a brief intervention program for cannabis use disorder","volume":"20","author":"Copeland","year":"2001","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drugalcdep.2005.03.027","article-title":"Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies","volume":"80","author":"Hart","year":"2005","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0052|cit52","unstructured":"Higgins JPT Lasserson T Chandler J Tovey D Churchill R Methodological expectations of Cochrane intervention reviews https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/mecir-manual"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"e076754","DOI":"10.1136\/bmj-2023-076754","article-title":"ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis","volume":"383","author":"Page","year":"2023","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008940.pub3","article-title":"Pharmacotherapies for cannabis dependence","author":"Nielsen","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD008940.pub4-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004837.pub3","article-title":"Cannabis and schizophrenia","author":"McLoughlin","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0058|cit58","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane 2023 Available from training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","article-title":"Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health","volume":"67","author":"O'Neill","year":"2014","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0060|cit60","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011 Available from handbook.cochrane.org\/archive\/v5.1"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/10550490802408936","article-title":"A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence","volume":"18","author":"Carpenter","year":"2009","journal-title":"American Journal on Addictions"},{"issue":"12","key":"10.1002\/14651858.CD008940.pub4-BIB0062|cit62","first-page":"888","article-title":"Six-month follow-up study of drug treatment for cannabis addiction: comparison study of four drugs","volume":"150","author":"Shoenfeld","year":"2011","journal-title":"Harefuah"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0063|cit63","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Page","year":"2024"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.6290","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0065|cit65","unstructured":"Sch\u0171nemann H Brozek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0066|cit66","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2019"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0067|cit67","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub4-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11419-016-0330-0","article-title":"The impact of Sativex (R) on cognitive function during treatment for cannabis withdrawal","volume":"32","author":"Bruno","year":"2013","journal-title":"Drug and Alcohol Review"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11419-016-0330-0","article-title":"Urinary cannabinoid levels during nabiximols (Sativex\u00ae)-medicated inpatient cannabis withdrawal","volume":"35","author":"Kevin","year":"2017","journal-title":"Forensic Toxicology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008940.pub4-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/0004867414529061","article-title":"Cannabinoid replacement therapy for management of cannabis withdrawal: a randomized controlled trial of nabiximols (Sativex\u00ae)","volume":"48","author":"Montebello","year":"2014","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"1-2","key":"10.1002\/14651858.CD008940.pub4-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drugalcdep.2010.05.010","article-title":"Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults","volume":"112","author":"Cornelius","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0073|cit73","first-page":"109","article-title":"Treatment trial and long-term follow-up evaluation among co-morbid youth with major depression and a cannabis use disorder","volume":"93","author":"Cornelius","year":"2012","journal-title":"Advances in Psychology Research"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"35-45","DOI":"10.1016\/S2215-0366(18)30427-9","article-title":"Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial","volume":"6","author":"D'Souza","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"S437","DOI":"10.1016\/S2215-0366(18)30427-9","article-title":"FAAH inhibitor treatment for cannabis dependence","volume":"40","author":"D'Souza","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1038\/npp.2017.263","article-title":"FAAH inhibitor PF-04457845 in the treatment of cannabis dependence","volume":"43","author":"D'Souza","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0077|cit77","doi-asserted-by":"crossref","unstructured":"Phase 2 trial shows encouraging target for treatment of cannabis use disorder Brown University Psychopharmacology Update 30 4 1 5 10.1002\/pu.30408","DOI":"10.1002\/pu.30408"},{"issue":"9","key":"10.1002\/14651858.CD008940.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.biopsych.2018.02.186","article-title":"The effect of fatty acid amide hydrolase inhibition on sleep architecture in cannabis withdrawal","volume":"83","author":"Skosnik","year":"2018","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0079|cit79","unstructured":"Fatty Acid Amide Hydrolase (FAAH) Inhibitor treatment of cannabis use disorder (CUD) (FAAH-I MULTI) https:\/\/clinicaltrials.gov\/study\/NCT03386487"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41386-022-01483-2","article-title":"Multisite randomized, double-blind, placebo-controlled, parallel group study of the efficacy, safety and tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor JZP150 (PF-04457845) in adults with cannabis use disorder (CUD)","volume":"47","author":"D'Souza","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD008940.pub4-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"865-74","DOI":"10.1016\/S2215-0366(20)30290-X","article-title":"Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial","volume":"7","author":"Freeman","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0082|cit82","unstructured":"Cannabidiol: a novel intervention for cannabis use problems? https:\/\/clinicaltrials.gov\/study\/NCT02044809"},{"issue":"10","key":"10.1002\/14651858.CD008940.pub4-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S2215-0366%2820%2930378-3","article-title":"Cannabidiol for cannabis use disorder: too high hopes?","volume":"7","author":"Hjorthoj","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41398-023-02410-9","article-title":"Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder","volume":"13","author":"Hua","year":"2023","journal-title":"Translational Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00213-022-06303-5","article-title":"Effect of four-week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder","volume":"240","author":"Lees","year":"2023","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0086|cit86","volume-title":"An Examination of Withdrawal Symptoms and Their Relationship with Outcomes in a Combined Behavioural and Pharmacological Intervention for Dependent Cannabis Users [thesis]","author":"Frewen","year":"2009"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0087|cit87","unstructured":"Frewen A Montebello ME Baillie A Rea F Effects of mirtazapine on withdrawal from dependent cannabis use 69th Annual Scientific Meeting of the College on Problems of Drug Dependence; 2007 June 16-21; Quebec City, Canada 2007 21 FREWEN2007"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0088|cit88","unstructured":"A double blind randomised control trial on the effects of mirtazapine during the acute withdrawal in patients attending a cannabis dependency program with focus on anxiety, depression and sleep disturbances https:\/\/anzctr.org.au\/ACTRN12607000286448.aspx"},{"issue":"8","key":"10.1002\/14651858.CD008940.pub4-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1176\/appi.ajp.2012.12010055","article-title":"A double-blind randomized controlled trial of N-Acetylcysteine in cannabis-dependent adolescents","volume":"169","author":"Gray","year":"2012","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.addbeh.2016.08.001","article-title":"Alcohol use during a trial of N-Acetylcysteine for adolescent marijuana cessation","volume":"63","author":"Squeglia","year":"2016","journal-title":"Addictive Behaviors"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jsat2015.12.003","article-title":"Low pretreatment impulsivity and high medication adherence increase the odds of abstinence in a trial of N-Acetylcysteine in adolescents with cannabis use disorder","volume":"63","author":"Bentzley","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.addbeh.2015.01.013","article-title":"Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence","volume":"45","author":"Roten","year":"2015","journal-title":"Addictive Behaviors"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub4-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.addbeh.2012.11.003","article-title":"Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial","volume":"38","author":"Roten","year":"2013","journal-title":"Addictive Behaviors"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.drugalcdep.2016.08.533","article-title":"Alcohol use during an N-Acetylcysteine cannabis cessation trial in adolescents","volume":"171","author":"Squeglia","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1002\/14651858.CD008940.pub4-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3109\/00952990.2013.878718","article-title":"Cigarette smoking during an N-Acetylcysteine-assisted cannabis cessation trial in adolescents","volume":"40","author":"McClure","year":"2014","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"5","key":"10.1002\/14651858.CD008940.pub4-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"E12-E13","DOI":"10.1097\/ADM.0000000000000902","article-title":"Cravings moderate the relationship between ethnicity and abstinence during CUD treatment","volume":"15","author":"Hammond","year":"2021","journal-title":"Journal of Addiction Medicine"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.drugalcdep.2018.07.018","article-title":"Tobacco use during cannabis cessation: use patterns and impact on abstinence in a national drug abuse treatment clinical trials network study","volume":"192","author":"McClure","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.addbeh.2018.09.023","article-title":"Corrigendum to \"The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine\"","volume":"89","author":"Tomko","year":"2019","journal-title":"Addictive Behaviors"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.drugalcdep.2017.04.020","article-title":"A randomized placebo-controlled trial of N-Acetylcysteine for cannabis use disorder in adults","volume":"177","author":"Gray","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drugalcdep.2017.12.005","article-title":"The effect of N-Acetylcysteine on alcohol use during a cannabis cessation trial","volume":"185","author":"Squeglia","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.cct.2014.08.011","article-title":"Achieving Cannabis Cessation - Evaluating N-Acetylcysteine Treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network","volume":"39","author":"McClure","year":"2014","journal-title":"Contemporary Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/ajad.12503","article-title":"Gender differences among treatment-seeking adults with cannabis use disorder: clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-Acetylcysteine treatment (ACCENT) study","volume":"26","author":"Sherman","year":"2017","journal-title":"American Journal on Addictions"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"105-111","DOI":"10.1016\/j.drugalcdep.2019.01.041","article-title":"Blunts versus joints: cannabis use characteristics and consequences among treatment-seeking adults","volume":"198","author":"Montgomery","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1002\/14651858.CD008940.pub4-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"505-14","DOI":"10.1037\/adb0000760","article-title":"Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder","volume":"36","author":"Sherman","year":"2022","journal-title":"Psychology of Addictive Behaviors"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"479-90","DOI":"10.1007\/s00213-019-05384-z","article-title":"Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder","volume":"237","author":"Tomko","year":"2020","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD008940.pub4-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"1965-74","DOI":"10.1111\/add.16226","article-title":"Who responds to a multi-component treatment for cannabis use disorder? Using multivariable and machine learning models to classify treatment responders and non-responders","volume":"118","author":"Tomko","year":"2023","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"108561","DOI":"10.1016\/j.jsat.2021.108561","article-title":"Race, psychosocial characteristics, and treatment outcomes among individuals undergoing treatment for cannabis use disorder: a latent profile analysis based on preferred method of using cannabis","volume":"131","author":"Ullrich","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub4-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"651-61","DOI":"10.1080\/00952990.2022.2097918","article-title":"Assessment of patient perception of treatment assignment and patient-reported outcomes in a cannabis use disorder trial","volume":"48","author":"Roydhouse","year":"2022","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jsat.2017.07.012","article-title":"Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life","volume":"81","author":"Hser","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"8","key":"10.1002\/14651858.CD008940.pub4-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/ajad.12622","article-title":"Nabilone pharmacotherapy for cannabis dependence: a randomized, controlled pilot study","volume":"26","author":"Hill","year":"2017","journal-title":"American Journal on Addictions"},{"issue":"24","key":"10.1002\/14651858.CD008940.pub4-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1007\/s00213-014-3611-5","article-title":"Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting","volume":"231","author":"Johnston","year":"2014","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD008940.pub4-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.5664\/jcsm.5090","article-title":"The effects of lithium carbonate supplemented with nitrazepam on sleep disturbance during cannabis abstinence","volume":"11","author":"Allsop","year":"2015","journal-title":"Journal of Clinical Sleep Medicine"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0113|cit113","first-page":"43","article-title":"A double blind, randomised, placebo controlled trial of lithium carbonate for the management of cannabis withdrawal [Conference Abstract]","volume":"32","author":"Johnston","year":"2013","journal-title":"Drug and Alcohol Review"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0114|cit114","first-page":"45","article-title":"Preliminary findings from a double blind, randomised, placebo controlled trial of lithium carbonate for the management of cannabis withdrawal [Conference Abstract]","volume":"31","author":"Johnston","year":"2012","journal-title":"Drug and Alcohol Review"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"209180","DOI":"10.1016\/j.josat.2023.209180","article-title":"Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder","volume":"156","author":"Lee","year":"2024","journal-title":"Journal of Substance Use and Addiction Treatment"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"A370","DOI":"10.1093\/sleep\/zsy061.999","article-title":"Targeting sleep in adults seeking treatment for cannabis use disorder","volume":"41","author":"Martin","year":"2018","journal-title":"Sleep"},{"issue":"9","key":"10.1002\/14651858.CD008940.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.biopsych.2018.02.184","article-title":"Targeting sleep disturbance in the treatment of cannabis use disorders","volume":"83","author":"Vandrey","year":"2018","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/10550490490265280","article-title":"Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium","volume":"13","author":"Levin","year":"2004","journal-title":"American Journal on Addictions"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","article-title":"Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial","volume":"116","author":"Levin","year":"2011","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"108765","DOI":"10.1016\/j.drugalcdep.2021.108765","article-title":"Non-abstinent treatment outcomes for cannabis use disorder","volume":"225","author":"Levin","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub4-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/add.12108","article-title":"A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders","volume":"108","author":"Levin","year":"2013","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.drugalcdep.2014.06.040","article-title":"Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with Venlafaxine-XR?","volume":"144","author":"Kelly","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.drugalcdep.2015.11.025","article-title":"Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial","volume":"159","author":"Levin","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"101-7","DOI":"10.1111\/ajad.12660","article-title":"Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder","volume":"27","author":"Brezing","year":"2018","journal-title":"American Journal on Addictions"},{"issue":"11","key":"10.1002\/14651858.CD008940.pub4-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1177\/10870547241264675","article-title":"Extended-release mixed amphetamine salts for comorbid adult attention-deficit\/hyperactivity disorder and cannabis use disorder: a pilot, randomized double-blind, placebo-controlled trial","volume":"28","author":"Levin","year":"2024","journal-title":"Journal of Atention Disorders"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0126|cit126","unstructured":"Treatment of cannabis use disorder among adults with comorbid attention-deficit\/\u200bhyperactivity disorder (MJ-ADHD) https:\/\/clinicaltrials.gov\/study\/NCT02803229"},{"issue":"9","key":"10.1002\/14651858.CD008940.pub4-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"1242-53","DOI":"10.1001\/jamainternmed.2019.1993","article-title":"Nabiximols for the treatment of cannabis dependence: a randomized clinical trial","volume":"179","author":"Lintzeris","year":"2019","journal-title":"JAMA Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008940.pub4-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/dar.13050","article-title":"Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence","volume":"39","author":"Mills","year":"2020","journal-title":"Drug Alcohol Review"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12888-018-1682-2","article-title":"Randomised controlled trial (RCT) of cannabinoid replacement therapy (nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol","volume":"18","author":"Bhardwaj","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0130|cit130","unstructured":"A randomised controlled trial of cannabidiol (CBD) for the treatment of cannabis use disorder (CUD) https:\/\/anzctr.org.au\/ACTRN12623000526673.aspx"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0131|cit131","article-title":"[Nabiximols as a substitute for cannabis]","volume":"164","author":"Dumont","year":"2020","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"108220","DOI":"10.1016\/j.drugalcdep.2020.108220","article-title":"Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: results from a placebo-controlled randomised trial","volume":"215","author":"Lintzeris","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/17523281.2012.693520","article-title":"A double-blind placebo control pilot study on the safety and tolerability of nabilone in marijuana users","volume":"6","author":"Lu","year":"2013","journal-title":"Mental Health and Substance Use"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13011-022-00493-z","article-title":"Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder","volume":"17","author":"Mills","year":"2022","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"109388","DOI":"10.1016\/j.drugalcdep.2022.109388","article-title":"Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: findings from a nabiximols versus placebo randomised controlled trial","volume":"234","author":"Montebello","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"108366","DOI":"10.1016\/j.drugalcdep.2020.108366","article-title":"Quetiapine treatment for cannabis use disorder","volume":"218","author":"Mariani","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/npp.2012.14","article-title":"A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults","volume":"37","author":"Mason","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.drugalcdep.2009.06.022","article-title":"A placebo-controlled trial of buspirone for the treatment of marijuana dependence","volume":"105","author":"McRae-Clark","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jsat.2015.05.002","article-title":"Concordance of direct and indirect measures of medication adherence in a treatment trial for cannabis dependence","volume":"57","author":"McRae-Clark","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub4-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1521-0391.2010.00076.x","article-title":"A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder","volume":"19","author":"McRae-Clark","year":"2010","journal-title":"American Journal on Addictions"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"17m02203","DOI":"10.4088\/PCC.17m02203","article-title":"Cannabis withdrawal in adults with attention-deficit\/hyperactivity disorder","volume":"20","author":"Chauchard","year":"2018","journal-title":"Primary Care Companion for CNS Disorders"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.drugalcdep.2015.08.013","article-title":"Buspirone treatment of cannabis dependence: a randomized, placebo-controlled trial","volume":"156","author":"McRae-Clark","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.addbeh.2016.04.014","article-title":"Gender differences in cannabis use disorder treatment: change readiness and taking steps predict worse cannabis outcomes for women","volume":"60","author":"Sherman","year":"2016","journal-title":"Addictive Behaviors"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/ajad.12324","article-title":"Vilazodone for cannabis dependence: a randomized, controlled pilot trial","volume":"25","author":"McRae-Clark","year":"2016","journal-title":"American Journal on Addictions"},{"issue":"Pt B","key":"10.1002\/14651858.CD008940.pub4-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"109111","DOI":"10.1016\/j.drugalcdep.2021.109111","article-title":"Varenicline as a treatment for cannabis use disorder: a placebo-controlled pilot trial","volume":"229","author":"McRae-Clark","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub4-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/adb.12350","article-title":"Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study","volume":"22","author":"Miranda","year":"2017","journal-title":"Addiction Biology"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0147|cit147","first-page":"265A","article-title":"Effects of topiramate on cannabis use among youth: an initial proof-of concept trial in the natural environment","volume":"39","author":"Treloar","year":"2015","journal-title":"Alcoholism: Clinical and Experimental Research"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/JCP.0000000000000843","article-title":"Predictors of topiramate tolerability in heavy cannabis-using adolescents and young adults: a secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"38","author":"Gray","year":"2018","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD008940.pub4-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1007\/s00213-021-05925-5","article-title":"Effects of topiramate on the association between affect, cannabis craving, and cannabis use in the daily life of youth during a randomized clinical trial","volume":"238","author":"Emery","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"108747","DOI":"10.1016\/j.drugalcdep.2021.108747","article-title":"Combined pharmacotherapy and evidence-based psychosocial cannabis treatment for youth and selection of cannabis-using friends","volume":"225","author":"Meisel","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"190","DOI":"10.15288\/jsad.2018.79.190","article-title":"Using ecological momentary assessment to identify mechanisms of change: an application from a pharmacotherapy trial with adolescent cannabis users","volume":"79","author":"Treloar Padovano","year":"2018","journal-title":"Journal of Studies on Alcohol and Drugs"},{"issue":"4","key":"10.1002\/14651858.CD008940.pub4-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaacop.2024.08.002","article-title":"A double-blind, placebo-controlled study of adjunctive topiramate in adolescents with co-occurring bipolar and cannabis use disorders","volume":"2","author":"Farrow","year":"2024","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry Open"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0153|cit153","unstructured":"Efficacy study of quetiapine plus topiramate for reducing cannabis consumption and bipolar mania https:\/\/clinicaltrials.gov\/study\/NCT00393978"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0154|cit154","unstructured":"Effectiveness study of dronabinol and BRENDA for the treatment of cannabis withdrawal https:\/\/clinicaltrials.gov\/study\/NCT00480441"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0155|cit155","unstructured":"Gabapentin treatment of cannabis dependence https:\/\/clinicaltrials.gov\/study\/NCT00974376"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0156|cit156","unstructured":"Hormones and reduction in co-users of marijuana and nicotine https:\/\/clinicaltrials.gov\/study\/NCT02579421"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0157|cit157","unstructured":"Effect of clonazepam on cannabis withdrawal and relapse in treatment-seeking patients https:\/\/clinicaltrials.gov\/study\/NCT02913924"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0158|cit158","unstructured":"Cannabidiol pharmacotherapy for adults with cannabis use disorder https:\/\/clinicaltrials.gov\/study\/NCT03102918"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0159|cit159","first-page":"63","article-title":"Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study","volume":"6","author":"Penetar","year":"2012","journal-title":"Substance Abuse: Research and Treatment"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.psychres.2017.01.027","article-title":"Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention","volume":"249","author":"Sherman","year":"2017","journal-title":"Psychiatry Research"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0161|cit161","doi-asserted-by":"publisher","first-page":"e0190768","DOI":"10.1371\/journal.pone.0190768","article-title":"Nabiximols combined with motivational enhancement\/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial","volume":"13","author":"Trigo","year":"2018","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"S422","DOI":"10.1038\/npp.2016.241","article-title":"Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence, a pilot study","volume":"41","author":"Trigo","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub4-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s13311-017-0543-x","article-title":"Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence: a pilot randomized clinical trial","volume":"14","author":"Trigo","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"8","key":"10.1002\/14651858.CD008940.pub4-BIB0164|cit164","first-page":"5228","article-title":"Effects of sub-chronic nabiximols on biological markers of individuals undergoing a clinical trial for the treatment of cannabis use disorder","volume":"15","author":"Wang","year":"2023","journal-title":"American Journal of Translational Research"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/00952990.2013.819362","article-title":"Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study","volume":"40","author":"Weinstein","year":"2014","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0166|cit166","unstructured":"Cannabidiol (CBD) for cannabis and mood disorders in adolescence (CCAMDA) https:\/\/anzctr.org.au\/ACTRN12616001001482.aspx"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12888-024-05616-3","article-title":"A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol","volume":"24","author":"Bhardwaj","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0168|cit168","unstructured":"Longitudinal outpatient treatment for cannabis use disorder (LOTUS) https:\/\/clinicaltrials.gov\/study\/NCT06107062"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"107250","DOI":"10.1016\/j.cct.2023.107250","article-title":"N-acetylcysteine for smoking cessation among dual users of tobacco and cannabis: protocol and rationale for a randomized controlled trial","volume":"131","author":"Herbst","year":"2023","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0170|cit170","unstructured":"N-acetylcysteine for smoking cessation in tobacco and cannabis co-use https:\/\/clinicaltrials.gov\/study\/NCT04627922"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0171|cit171","unstructured":"Nabilone & marijuana addiction https:\/\/clinicaltrials.gov\/study\/NCT01025700"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0172|cit172","unstructured":"Substance misuse to psychiatric disorders for cannabis https:\/\/clinicaltrials.gov\/study\/NCT03485274"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0173|cit173","unstructured":"Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2) https:\/\/clinicaltrials.gov\/study\/NCT05322941"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0174|cit174","unstructured":"Effect of PP-01 on cannabis withdrawal syndrome https:\/\/clinicaltrials.gov\/study\/NCT05494437"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0175|cit175","unstructured":"Clinical trial of n-acetylcysteine versus placebo efficacy in the cannabis withdrawal https:\/\/clinicaltrials.gov\/show\/NCT01439828"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0176|cit176","unstructured":"Naltrexone as anti-craving medication in cannabis addicts https:\/\/onderzoekmetmensen.nl\/en\/trial\/28347"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0177|cit177","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008940","article-title":"Pharmacotherapies for cannabis withdrawal","author":"Marshall","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008940.pub4-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.20240841","article-title":"Reductions in substance use as outcome targets for treatment development","volume":"181","author":"Compton","year":"2024","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jsat.2013.07.005","article-title":"Differences in the acceptability of non-abstinence goals by type of drug among American substance abuse clinicians","volume":"46","author":"Rosenberg","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/08897077.2015.1015702","article-title":"Acceptability of non-abstinence goals among students enrolled in addiction studies programs across the United States","volume":"37","author":"Davis","year":"2016","journal-title":"Substance Abuse"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD008940.pub4-BIB0181|cit181","first-page":"5","article-title":"Treatment of patients with substance use disorders","volume":"164","author":"Kleber","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD008940.pub4-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ajp.20230508","article-title":"Association of cannabis use reduction with improved functional outcomes: an exploratory aggregated analysis from seven cannabis use disorder treatment trials to extract data-driven cannabis reduction metrics","volume":"181","author":"McClure","year":"2024","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"107993","DOI":"10.1016\/j.drugalcdep.2020.107993","article-title":"The state of clinical outcome assessments for cannabis use disorder clinical trials: a review and research agenda","volume":"212","author":"Loflin","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"103295","DOI":"10.1016\/j.drugpo.2021.103295","article-title":"Pharmacotherapies for cannabis use disorder: a systematic review and network meta-analysis","volume":"97","author":"Bahji","year":"2021","journal-title":"International Journal of Drug Policy"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub4-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M19-1105","article-title":"Pharmacotherapy for the treatment of cannabis use disorder: a systematic review","volume":"172","author":"Kondo","year":"2020","journal-title":"Annals of Internal Medicine"},{"issue":"5-6","key":"10.1002\/14651858.CD008940.pub4-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/09540261.2023.2231540","article-title":"Unravelling the landscape of cannabis craving pharmacological treatments: a PRISMA-guided review of evidence","volume":"35","author":"Preto","year":"2023","journal-title":"International Review of Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"867878","DOI":"10.3389\/fpsyt.2022.867878","article-title":"Cannabinoids in the treatment of cannabis use disorder: systematic review of randomized controlled trials","volume":"13","author":"Vuilleumier","year":"2022","journal-title":"Frontiers Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"1144276","DOI":"10.3389\/fpsyt.2023.1144276","article-title":"Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder","volume":"14","author":"Phan","year":"2023","journal-title":"Frontiers Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0189|cit189","doi-asserted-by":"publisher","first-page":"107283","DOI":"10.1016\/j.addbeh.2022.107283","article-title":"N-acetyl cysteine in the treatment of cannabis use disorder: a systematic review of clinical trials","volume":"129","author":"Sharma","year":"2022","journal-title":"Addictive Behaviours"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub4-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s40429-021-00404-5","article-title":"Racial and ethnic differences in cannabis use and cannabis use disorder: implications for researchers","volume":"9","author":"Montgomery","year":"2022","journal-title":"Current Addiction Reports"},{"issue":"8","key":"10.1002\/14651858.CD008940.pub4-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S2215-0366(22)00160-2","article-title":"Racial and ethnic differences in alcohol, cannabis, and illicit substance use treatment: a systematic review and narrative synthesis of studies done in the USA","volume":"9","author":"Jordan","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub4-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.drugalcdep.2012.05.033","article-title":"Moderating effects of race in clinical trial participation and outcomes among marijuana-dependent young adults","volume":"126","author":"Montgomery","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub4-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1037\/pha0000649","article-title":"Associations of alcohol use disorder, cannabis use disorder, and nicotine dependence with concurrent opioid use disorder in U.S. adults","volume":"31","author":"Harton","year":"2023","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub4-BIB0194|cit194","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.psychres.2017.01.027","article-title":"Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention","volume":"249","author":"Sherman","year":"2017","journal-title":"Psychiatry Research"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub4-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40501-015-0038-5","article-title":"Outcome measures in medication trials for substance use disorders","volume":"2","author":"McCann","year":"2015","journal-title":"Current Treatment Options in Psychiatry"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:05:57Z","timestamp":1790060757000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008940.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":195,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008940.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}